Acadia Pharmaceuticals Inc. (ACAD)
Why Is Acadia (ACAD) Down 12.9% Since Last Earnings Report?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Acadia Pharmaceuticals upgraded on improve risk-reward profile following pullback
Bank of America upgraded Acadia Pharmaceuticals (NASDAQ:ACAD) to 'Buy' from 'Neutral', arguing that a recent pullback in the stock has created a more attractive risk-reward profile for investors. The analysts maintained a $29 price objective on the shares, which traded up 6% at $22 on Wednesday afternoon, and wrote that the roughly 25% decline in the stock is “not related to fundamentals and more related to YTD macro factors.
ACADIA Pharmaceuticals Inc. $ACAD Shares Sold by First Trust Advisors LP
First Trust Advisors LP lessened its stake in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) by 20.2% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,943,152 shares of the biopharmaceutical company's stock after selling 491,224 shares during the quarter. First Trust
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Revised)
Acadia plans re-examination after CHMP rejects Rett syndrome drug trofinetide in the EU, delays potential approval despite positive LAVENDER study results.
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU
Acadia plans re-examination after CHMP rejects Rett syndrome drug trofinetide in the EU, delays potential approval despite positive LAVENDER study results.
ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
Acadia beats Q4 EPS estimates as Nuplazid and Daybue lift revenues 9%, but sales miss and EU setback cloud trofinetide outlook with 2026 sales at $1.22-$1.28 billion.
ACADIA Pharmaceuticals Inc. (ACAD) Q4 2025 Earnings Call Transcript
ACADIA Pharmaceuticals Inc. (ACAD) Q4 2025 Earnings Call Transcript
Acadia Pharmaceuticals (ACAD) Q4 Earnings Top Estimates
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.17 per share a year ago.
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates
Let us look at some drug/biotech stocks, ZTS, PCRX, APLS, ACAD and DNLI, which are poised to beat on fourth-quarter 2025 earnings.
Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU
ACAD expects a negative CHMP opinion on trofinetide marketing application for Rett syndrome, likely delaying a potential EU approval.
Why Acadia (ACAD) is Poised to Beat Earnings Estimates Again
Acadia (ACAD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
